Protagenic Therapeutics, Inc.new (PTIX) shareholders
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bigger Capital Fund GP, LLC Joint filing with Bigger Capital Fund L P (5.75%), Bigger Michael (5.75%) | 50,000 | 5.75% | 13G (passive) | Jul 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTIX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| DRW Securities, LLC | 41,783 | 2.31% | $16.38K | – | 0.00% |
| FNY Investment Advisers, LLC | 25,000 | 1.38% | $9.00K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2 | 0M | 3.7% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q1 2026 | 4 | 0M | 3.7% | 1 / 0 | 1 / 9 | 0M | 0M |
| Q4 2025 | 12 | 0M | 6.4% | 4 / 4 | 1 / 3 | 0M | 0M |
| Q3 2025 | 11 | 0M | 5.5% | 4 / 3 | 1 / 4 | 0M | 0M |
| Q2 2025 | 11 | 0M | 3.9% | 11 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Garo H. Armen | EXEC. CHAIR & PRINCIPAL OFF, Director | 323,533 | 17.87% | Aug 24, 2026 |
| Barrett Evans | ex CEO, Director, 10% owner | – | – | Oct 24, 2025 |
| Crest Capital LLC Mammoth | ex CEO, Director, 10% owner | 18,233 | 1.01% | Oct 24, 2025 |
| Capital LLC EMC2 | ex CEO, Director, 10% owner | – | – | Oct 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 21, 2026 | Buy | +20,000 | $0.65 | $13.00K | 73,533 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 20, 2026 | Buy | +16,634 | $0.59 | $9.81K | 53,533 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 19, 2026 | Buy | +2,700 | $0.35 | $945 | 36,899 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 11, 2026 | Buy | +2,220 | $0.32 | $710 | 34,199 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 6, 2026 | Buy | +685 | $0.22 | $151 | 31,979 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF, Director | Aug 5, 2026 | Buy | +5,000 | $0.26 | $1.30K | 31,294 |
| Garo H. Armen EXEC. CHAIR & PRINCIPAL OFF., Director | Jul 30, 2026 | Buy | +26,291 | $0.18 | $4.73K | 26,291 |
| Alexander K. Arrow Chief Financial Officer | Oct 12, 2023 | Buy | +8,000 | $0.81 | $6.48K | 45,815 |
| Alexander K. Arrow Chief Financial Officer | May 18, 2022 | Buy | +8,000 | $0.72 | $5.76K | 151,260 |
| Alexander K. Arrow Chief Financial Officer | May 17, 2022 | Buy | +23,000 | $0.71 | $16.33K | 143,260 |
| Khalil Barrage Director | May 3, 2021 | Option exercise | +150,000 | $1.25 | $187.50K | 245,000 |
| Khalil Barrage Director | May 3, 2021 | Option exercise | +45,000 | $1.75 | $78.75K | 290,000 |
| Khalil Barrage Director | May 3, 2021 | Option exercise | +120,000 | $1.75 | $210.00K | 410,000 |
| Khalil Barrage Director | May 3, 2021 | Option exercise | +45,000 | $1.25 | $56.25K | 95,000 |
| Alexander K. Arrow Chief Financial Officer | Apr 30, 2021 | Buy | +1,000 | $2.29 | $2.29K | 120,260 |
| Alexander K. Arrow Chief Financial Officer | Apr 29, 2021 | Buy | +1,000 | $2.29 | $2.29K | 119,260 |
| Khalil Barrage Director | Aug 8, 2016 | Award | +150,000 | $1.25 | $187.50K | 245,000 |
| Garo H. Armen See Remarks, Director, 10% owner | Jun 17, 2016 | Buy | +60,211 | $1.25 | $75.26K | 4,299,379 |
| Gregory Ekizian Director | Jun 17, 2016 | Award | +45,000 | $1.25 | $56.25K | 645,000 |
| Khalil Barrage Director | Jun 17, 2016 | Award | +45,000 | $1.25 | $56.25K | 245,000 |
| Garo H. Armen See Remarks, Director, 10% owner | Jun 17, 2016 | Award | +500,000 | $1.25 | $625.00K | 4,239,168 |
| Robert Benjamin Stein Director | Jun 17, 2016 | Award | +40,000 | $1.25 | $50.00K | 240,000 |
| Joshua Silverman Director | Jun 17, 2016 | Award | +45,000 | $1.25 | $56.25K | 45,000 |
| Alexander K. Arrow Chief Financial Officer | Jun 17, 2016 | Award | +140,000 | $1.25 | $175.00K | 358,260 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +900 | $1.98 | $1.78K | 119,920 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +1,334 | $1.99 | $2.65K | 121,254 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +569 | $2.07 | $1.18K | 121,897 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +300 | $2.08 | $624 | 122,197 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +1,758 | $2.09 | $3.67K | 123,955 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +74 | $2.00 | $148 | 121,328 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +266 | $1.97 | $524 | 119,020 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +74 | $2.00 | $148 | 448,194 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +1,334 | $1.99 | $2.65K | 448,120 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +900 | $1.98 | $1.78K | 446,786 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +266 | $1.97 | $524 | 445,886 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +1,758 | $2.09 | $3.67K | 450,821 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +300 | $2.08 | $624 | 449,063 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 13, 2010 | Buy | +569 | $2.07 | $1.18K | 448,763 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +600 | $1.63 | $978 | 110,055 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +300 | $1.60 | $480 | 109,455 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +200 | $1.59 | $318 | 109,155 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +5,000 | $1.90 | $9.50K | 118,754 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +100 | $1.64 | $164 | 110,155 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +100 | $1.70 | $170 | 110,255 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +3,499 | $1.79 | $6.26K | 113,754 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +5,000 | $1.90 | $9.50K | 445,620 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +3,499 | $1.79 | $6.26K | 440,620 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +100 | $1.70 | $170 | 437,121 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +100 | $1.64 | $164 | 437,021 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +600 | $1.63 | $978 | 436,921 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +300 | $1.60 | $480 | 436,321 |
| Raymond Musci Exec VP, Corporate Development, Director | Dec 10, 2010 | Buy | +200 | $1.59 | $318 | 436,021 |
| Mark Dyne Director, 10% owner | Jun 3, 2010 | Other | −20,000 | – | – | 746,369 |
| Thomas Plotts Interim CFO | Mar 31, 2010 | Tax withholding | −9,718 | $0.82 | $7.97K | 28,619 |
| Thomas Plotts Interim CFO | Mar 31, 2010 | Option exercise | +25,000 | – | – | 38,337 |
| Jerome A. Chazen Director | Jan 20, 2010 | Other | +41,049 | – | – | 53,234 |
| Robert S. Ellin Director, 10% owner | Jan 6, 2010 | Other | −1,323,467 | – | – | 1,792,695 |
| Robert S. Ellin Director, 10% owner | Dec 21, 2009 | Buy | +5,376 | $0.60 | $3.23K | 3,116,262 |
| Robert S. Ellin Director, 10% owner | Dec 14, 2009 | Buy | +527,683 | $0.65 | $342.99K | 3,110,886 |
| Robert S. Ellin Director, 10% owner | Dec 9, 2009 | Buy | +21,947 | $0.67 | $14.70K | 2,583,203 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Protagenic Therapeutics, Inc.new's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,176 shares on Sep 1, 2026 over the last 90 days.
See a number that looks wrong?